Vitamin K2 Bone Randomized Trial: What the Evidence Says

Quick Answer

Vitamin K2 Bone Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 preclinical study, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Experimental and clinical evidence now suggests that vitamin K influences skeletal muscle through both γ-carboxylation-dependent pathways-mediated by osteocalcin, matrix Gla protein (MGP), and growth arrest-specific 6 (Gas6)-and through non-carboxylation mechanisms, including anti-inflammatory, antioxidant, mitochondrial-regulatory, and ferroptosis-suppressing effects. [Ran X (2026); evidence level 4]
• Beyond age-related sarcopenia, vitamin K may also play a potentially protective role in muscle dysfunction associated with chronic diseases, including dialysis-related cramps and metabolic disorders. [Ran X (2026); evidence level 4]
• Together with vitamin K2, it participates in the fine-tuning of mineral metabolism and vascular health, potentially modulating cardiometabolic risk through intertwined endocrine and paracrine pathways. [D'Elia S (2025); evidence level 4]
• Observational and mechanistic studies consistently link low serum 25(OH)D concentrations with hypertension, insulin resistance, heart failure, and increased cardiovascular mortality. [D'Elia S (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For vitamin k2 bone randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Ran X (2026). Vitamin K and muscle health: mechanisms and clinical perspectives in sarcopenia and beyond: narrative review.. DOI: 10.3389/fnut.2026.1726483. PMCID: PMC12979126. PMID: 41835384. https://pmc.ncbi.nlm.nih.gov/articles/PMC12979126/
• D'Elia S (2025). Modulation of Cardiometabolic Risk by Vitamin D and K2: Simple Supplementation or Real Drug? Uncovering the Pharmacological Properties.. DOI: 10.3390/ijms27010298. PMCID: PMC12785717. PMID: 41516172. https://pmc.ncbi.nlm.nih.gov/articles/PMC12785717/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.